• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc. (Amendment)

    2/14/24 5:06:51 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DNA alert in real time by email
    SC 13G/A 1 austinche-13gxa.htm SC 13G/A Document

     
    Securities and Exchange Commission
    Washington, D.C. 20549
     
     
    Schedule 13G
    (Rule 13d-102) 
    Information to be Included in Statements Filed Pursuant
    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed
    Pursuant to § 240.13d-2 
    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)*
     
     
    Ginkgo Bioworks Holdings, Inc.
    (Name of Issuer)
    Class A Common Stock
    (Title of Class of Securities)
    37611X100
    (CUSIP Number)
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☐ Rule 13d-1(b) 
    ☒ Rule 13d-1(c) 
    ☐ Rule 13d-1(d) 
     
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.



    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

      1   
      Names of Reporting Persons
     
      Austin Che
      2 
      Check the Appropriate Box if a Member of a Group
     
      (a)  ☐        (b)  ☐
      3 
      SEC Use Only
     
      4 
      Citizenship or Place of Organization
     
      United States

    Number of
    Shares
     Beneficially 
    Owned by
    Each
    Reporting
    Person
    With
      5    
      Sole Voting Power
     
      95,898,483

      6  
      Shared Voting Power
     
      0
      7  
      Sole Dispositive Power
     
      95,898,483
      8  
      Shared Dispositive Power
     
      0

      9   
      Aggregate Amount Beneficially Owned by Each Reporting Person
     
      95,898,483
    10 
      Check if the Aggregate Amount in Row (9) Excludes Certain Shares
     
      Not Applicable
    11 
      Percent of Class Represented by Amount in Row 9
     
      5.6%
    12 
      Type of Reporting Person
     
      IN









    ITEM 1. (a) Name of Issuer:
    Ginkgo Bioworks Holdings, Inc. (the “Issuer”).
          (b) Address of Issuer’s Principal Executive Offices:
    27 Drydock Avenue, 8th Floor, Boston, MA 02210.
    ITEM 2. (a) Name of Person Filing:
    Austin Che (the “Reporting Person”).
          (b) Address or Principal Business Office:
    The business address of the Reporting Person is c/o Ginkgo Bioworks Holdings, Inc., 27 Drydock Avenue, 8th Floor, Boston, MA 02210.
          (c) Citizenship of each Reporting Person is:
    The Reporting Person is a citizen of the United States.
          (d) Title of Class of Securities:
    Class A common stock, par value $0.0001 per share (“Class A Common Stock”).
          (e) CUSIP Number:
    37611X100
    ITEM 3.
    Not applicable.
    ITEM 4. Ownership.
    (a-c) 
    The ownership information presented below represents beneficial ownership of Class A Common Stock of the Issuer as of December 31, 2023, based upon 1,639,885,251 shares of Class A Common Stock outstanding as of December 31, 2023, and 80,147,413 shares of Class A Common Stock issuable upon conversion of shares of Class B common stock, $0.0001 per share (“Class B Common Stock”) beneficially owned by the Reporting Person.
     
     • Amount beneficially owned: 95,898,483
     
     • Percent of Class: 5.6%
     
     • Number of shares the Reporting Person has:
     
     • Sole power to vote or direct the vote: 95,898,483
     
     • Shared power to vote: 0
     
     • Sole power to dispose or direct the disposition of: 95,898,483
     
     • Shared power to dispose or direct the disposition of: 0
    The share amount reported herein consists of (i) 13,751,070 shares of Class A Common Stock of the Issuer held of record by the Reporting Person; (ii) 1,000,000 shares of Class A Common Stock of the Issuer held of record by a revocable spousal trust, of which the Reporting Person may be deemed to hold investment and voting discretion; (iii) 1,000,000 shares of Class A Common Stock of the Issuer held of record by a family trust, of which the Reporting Person may be deemed to hold investment and voting discretion; (iv) 76,927,069 shares of Class A Common Stock issuable upon conversion of shares of Class B Common Stock of the Issuer held of record by the Austin Che Revocable Trust, of which the Reporting Person is the sole trustee; (v) 822,206 shares of Class A Common Stock issuable upon conversion of shares of Class B Common Stock held of record by the Austin Che Irrevocable Trust, of which the Reporting Person may be deemed to hold investment and voting discretion; (vi)



    77,794 shares of Class A Common Stock issuable upon conversion of shares of Class B Common Stock held of record by an irrevocable marital trust, of which the Reporting Person may be deemed to hold investment and voting discretion; and (vii) 2,320,344 shares of Class A Common Stock issuable upon conversion of shares of Class B Common Stock of the Issuer held of record by the Reporting Person. The shares of Class B Common Stock may be redeemed by the holder at any time for shares of Class A Common Stock on a one-to-one basis.
    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
    Not applicable.  
    ITEM 6. Ownership of More Than Five Percent on Behalf of Another Person.
    Not applicable.
    ITEM 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company.
    Not applicable.
    ITEM 8. Identification and Classification of Members of the Group.
    Not applicable.
    ITEM 9. Notice of Dissolution of Group.
    Not applicable.
    ITEM 10. Certification.
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11. 


    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Date: February 14, 2024
     
    By: /s/ Austin Che
    Name: Austin Che


    Get the next $DNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNA

    DatePrice TargetRatingAnalyst
    5/15/2024Neutral → Sell
    BTIG Research
    5/10/2024Mkt Perform → Underperform
    William Blair
    11/14/2023$3.50 → $2.50Outperform → Mkt Perform
    Raymond James
    11/9/2023Buy → Neutral
    BTIG Research
    6/2/2023$3.00 → $1.25Neutral → Sell
    Goldman
    5/11/2023Outperform → Mkt Perform
    William Blair
    11/29/2022$6.00Buy
    Berenberg
    10/4/2022$5.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $DNA
    SEC Filings

    See more
    • SEC Form 144 filed by Ginkgo Bioworks Holdings Inc.

      144 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

      5/21/25 4:11:12 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

      5/21/25 4:07:27 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Ginkgo Bioworks Holdings Inc.

      10-Q - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

      5/6/25 5:04:29 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer

      BOSTON, May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA, ", Ginkgo", or the ", Company", )), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company's Chief Financial Officer, intends to resign from his role at the Company on May 30, 2025 to accept a position at another organization and Steven Coen, CPA, the Company's Chief Accounting Officer, will become Chief Financial Officer, effective upon Mr. Dmytruk's resignation. Mr. Coen joined the Company on May 1, 2023 with over 30 years of public accounting

      5/21/25 4:05:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Twist Bioscience and Ginkgo Bioworks Revise Collaboration

      New terms provide Twist with key license to long DNA technology and assets Ginkgo to continue ordering from Twist with no purchase minimums Twist Bioscience Corporation (NASDAQ:TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that the companies have entered into an updated collaboration renegotiated from a prior contract signed in 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508352416/en/ Under the terms of the revised three-year $15

      5/8/25 8:00:00 AM ET
      $DNA
      $TWST
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks Reports First Quarter 2025 Financial Results

      Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON, May 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investo

      5/6/25 5:00:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Ginkgo Bioworks downgraded by BTIG Research

      BTIG Research downgraded Ginkgo Bioworks from Neutral to Sell

      5/15/24 7:33:13 AM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks downgraded by William Blair

      William Blair downgraded Ginkgo Bioworks from Mkt Perform to Underperform

      5/10/24 7:33:29 AM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks downgraded by Raymond James with a new price target

      Raymond James downgraded Ginkgo Bioworks from Outperform to Mkt Perform and set a new price target of $2.50 from $3.50 previously

      11/14/23 9:04:22 AM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sankar Shyam bought $514,750 worth of shares (625,000 units at $0.82), increasing direct ownership by 36% to 2,356,874 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      5/16/24 5:08:50 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sloan Harry bought $271,815 worth of shares (297,619 units at $0.91), increasing direct ownership by 71% to 718,540 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      5/14/24 5:16:23 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer

      BOSTON, May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE:DNA, ", Ginkgo", or the ", Company", )), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmytruk, the Company's Chief Financial Officer, intends to resign from his role at the Company on May 30, 2025 to accept a position at another organization and Steven Coen, CPA, the Company's Chief Accounting Officer, will become Chief Financial Officer, effective upon Mr. Dmytruk's resignation. Mr. Coen joined the Company on May 1, 2023 with over 30 years of public accounting

      5/21/25 4:05:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sojitz Corporation and Ginkgo Bioworks Announce Plans to Use Synthetic Biology R&D Services to Accelerate Sustainable Manufacturing in Japan

      Sojitz intends to use its extensive network to help Ginkgo foster business connections within the Japanese bioeconomy TOKYO and BOSTON, May 14, 2024 /PRNewswire/ -- Sojitz, a large Japanese general trading company with extensive networks within the Japanese bioeconomy, and Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a binding definitive agreement. Together, Sojitz and Ginkgo aim to build connections with key Japanese businesses and encourage the use of synthetic biology to develop sustainable production processes.

      5/14/24 6:00:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • IdeeLab Joins the Ginkgo Technology Network to Provide Agriculture Companies in Brazil with End-to-End Product Development & Manufacturing Service

      Ginkgo customers will now have access to IdeeLab's local strain discovery capabilities, as well as the ability to manufacture next-generation products in IdeeLab's manufacturing facilities PIRACICABA, Brazil, April 8, 2024 /PRNewswire/ -- IdeeLab Biotechnology, a Brazilian company aiming to develop innovations and biological solutions for agriculture, today announced that is has entered into an agreement with Ginkgo Bioworks (NYSE:DNA), which is building the leading platform for cell programming and biosecurity, to join the Ginkgo Technology Network. The Ginkgo Technology Netw

      4/8/24 7:00:00 AM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

      SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

      11/14/24 4:31:49 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

      SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

      11/12/24 3:58:52 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

      SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

      11/4/24 11:56:06 AM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Coen Steven P. sold $2,624 worth of shares (346 units at $7.58) and converted options into 743 shares, increasing direct ownership by 5% to 9,216 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      5/22/25 4:06:27 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Dmytruk Mark E. converted options into 1,479 shares and sold $5,355 worth of shares (706 units at $7.58), increasing direct ownership by 2% to 46,226 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      5/22/25 4:05:15 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Coen Steven P. sold $7,261 worth of shares (997 units at $7.28) and converted options into 1,804 shares, increasing direct ownership by 10% to 8,819 units (SEC Form 4)

      4 - Ginkgo Bioworks Holdings, Inc. (0001830214) (Issuer)

      4/23/25 5:03:07 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNA
    Financials

    Live finance-specific insights

    See more
    • Ginkgo Bioworks Reports First Quarter 2025 Financial Results

      Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON, May 6, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended March 31, 2025. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investo

      5/6/25 5:00:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks Announces Date of First Quarter 2025 Results Presentation

      Presentation and Q&A session scheduled for post-market on Tuesday, May 6, 2025 BOSTON, April 29, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2025, on Tuesday, May 6, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobiowor

      4/29/25 4:00:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results

      Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target Cell Engineering revenue of $35 million in the fourth quarter of 2024, representing 29% growth over 2023 BOSTON, Feb. 25, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2024. The update, including a webcast slide presentation with additional details on the fourth quarter and full year, as well as supplemental financial

      2/25/25 5:00:00 PM ET
      $DNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care